Combining [ 177 Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer.

Hartmut Rauch Carolin Kitzberger Kirti Janghu Pavithra Hawarihewa Nghia T NguyenYu MinSimone Ballke Katja Steiger Wolfgang Andreas Weber Susanne Kossatz

Published in: European journal of nuclear medicine and molecular imaging (2024)

The addition of PARPi can markedly improve the potency of SSTR2-targeted PRRT in SCLC models in SSTR2 low-expressing tumors. Further evaluation in humans seems justified based on the results as novel treatment options for SCLC are urgently needed.

Keyphrases

small cell lung cancer
dna damage
pet ct
dna repair
pet imaging
brain metastases
oxidative stress